AstraZeneca address cardiovascular & renal risks in diabetes

Alzheimer's Society says women should not be alarmed over small hormone therapy risk.
Alzheimer's Society says that women should continue taking prescribed hormone therapy.

AstraZeneca and MedImmune, its global biologics research and development arm, will present more than 50 abstracts from the Company’s Cardiovascular, Renal & Metabolism (CVRM) therapy area at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany.

This latest research underscores AstraZeneca’s expansive clinical trial programme and comprehensive approach to advancing clinical practice in the management of cardiovascular, renal and metabolic (CaReMe) diseases. Data to be presented from the Company’s portfolio include Farxiga (dapagliflozin) and Bydureon (exenatide extended-release) in type-2 diabetes (T2D), alone and in combination with other diabetes therapies. Highlights also include data on the potential of Farxiga in type-1 diabetes (T1D) and additional pre-clinical and clinical data for MEDI0382, a potential first-in-class oxyntomodulin-like peptide for type-2 diabetes and the latest candidate in the Company’s CVRM pipeline.

Highlights include several abstracts evaluating the effects of Farxiga alone and in combination in treating T2D, and in patients with CV (including heart failure) and renal risk factors. Research into CaReMe diseases includes a recent trial on CV outcomes and mortality in people with T2D and associated comorbidities. The results will illustrate the importance of identifying novel protection strategies for various T2D-related comorbidities, including heart failure and chronic kidney disease, and may have implications for investigating risk in T2D patients.

For patients with T1D, insulin is the standard therapy with no oral treatment options approved to date. The latest sub-analysis of pooled data from the DEPICT (Dapagliflozin Evaluation in Patients with Inadequately Controlled Type-1 Diabetes) clinical trial programme (DEPICT-1 and DEPICT-2) features an evaluation on the effect of Farxiga in T1D patients taking adjustable insulin treatment. The analysis will look at two composite endpoints, including those determining instances of weight gain, severe hypoglycaemia and diabetic ketoacidosis (DKA). Farxiga is currently not approved in T1D.

AstraZeneca will also present an analysis from the CVD-REAL study which evaluated the efficacy and safety of SGLT2 inhibitors vs. other glucose-lowering medicines. This additional analysis will look at data across a larger number of countries and patients, with a longer duration of follow up than previously evaluated.

Ludovic Helfgott, Vice President, Cardiovascular, Renal and Metabolism at AstraZeneca, said: “Our key data at EASD will expand understanding around the persistent cardiovascular and renal risks in patients with type-2 diabetes, as well as the unmet need in type-1 diabetes, where we are at the forefront of advancing treatment for patients. We are constantly pursuing science to advance the management of cardiovascular, renal and metabolic diseases to improve patient outcomes.”